Selected research
Market Structure
Global Untargeted Metabolomics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Untargeted Metabolomics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Untargeted Metabolomics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Untargeted Metabolomics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Untargeted Metabolomics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Untargeted Metabolomics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Untargeted Metabolomics include Creative Proteomics, Metabolon, Alfa Chemistry, Novelgene Technologies, MtoZ-Biolabs Inc., CD Genomics, Metware Biotechnology Inc (Metware), BGI Genomics and APPLIED PROTEIN TECHNOLOGY, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Untargeted Metabolomics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Untargeted Metabolomics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Untargeted Metabolomics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Untargeted Metabolomics market size, projected growth trends, production technologies, key applications, and end-use industries.
Untargeted Metabolomics Segment by Company
Creative Proteomics
Metabolon
Alfa Chemistry
Novelgene Technologies
MtoZ-Biolabs Inc.
CD Genomics
Metware Biotechnology Inc (Metware)
BGI Genomics
APPLIED PROTEIN TECHNOLOGY
Suzhou PANOMIX Biomedical Tech Co.,Ltd
OBiO Technology ( Shanghai ) Corp.,Ltd.
Beijing Huayi innovation & BioTechnology Co., Ltd
Abace Biotechnology
Metabo-Profile
Untargeted Metabolomics Segment by Type
Plant Untargeted Metabolomics
Human Untargeted Metabolomics
Other
Untargeted Metabolomics Segment by Application
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
Untargeted Metabolomics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Untargeted Metabolomics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Untargeted Metabolomics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Untargeted Metabolomics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Untargeted Metabolomics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Untargeted Metabolomics industry.
Chapter 3: Detailed analysis of Untargeted Metabolomics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Untargeted Metabolomicsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Plant Untargeted Metabolomics
- Human Untargeted Metabolomics
- Other
Applications
- Academic and Research Institutions
- Pharmaceutical and Biotechnology Companies
Companies covered
- Creative Proteomics
- Metabolon
- Alfa Chemistry
- Novelgene Technologies
- MtoZ-Biolabs Inc.
- CD Genomics
- Metware Biotechnology Inc (Metware)
- BGI Genomics
- APPLIED PROTEIN TECHNOLOGY
- Suzhou PANOMIX Biomedical Tech Co.,Ltd
- OBiO Technology ( Shanghai ) Corp.,Ltd.
- Beijing Huayi innovation & BioTechnology Co., Ltd
- Abace Biotechnology
- Metabo-Profile
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Untargeted Metabolomics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Plant Untargeted Metabolomics
- 1.2.3 Human Untargeted Metabolomics
- 1.2.4 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global Untargeted Metabolomics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Academic and Research Institutions
- 1.3.3 Pharmaceutical and Biotechnology Companies
- 1.4 Global Market Growth Prospects
- 1.5 Global Untargeted Metabolomics Growth Trends by Region
- 1.5.1 Global Untargeted Metabolomics Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Untargeted Metabolomics Market Size by Region (2021-2026)
- 1.5.3 Untargeted Metabolomics Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Untargeted Metabolomics Market Dynamics
- 2.1 Untargeted Metabolomics Industry Trends
- 2.2 Untargeted Metabolomics Industry Drivers
- 2.3 Untargeted Metabolomics Industry Opportunities and Challenges
- 2.4 Untargeted Metabolomics Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Untargeted Metabolomics Revenue by Company (2021-2026)
- 3.2 Global Untargeted Metabolomics Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Untargeted Metabolomics Key Company Head office and Area Served
- 3.4 Global Untargeted Metabolomics Company, Product Type & Application
- 3.5 Global Untargeted Metabolomics Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Untargeted Metabolomics Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Untargeted Metabolomics Players Market Share by Revenue in 2025
- 3.6.3 2025 Untargeted Metabolomics Tier 1, Tier 2, and Tier 3
4 Untargeted Metabolomics Market by Type
- 4.1 Global Untargeted Metabolomics Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Untargeted Metabolomics Market Size by Type (2021-2032)
- 4.3 Global Untargeted Metabolomics Market Size Share by Type (2021-2032)
5 Untargeted Metabolomics Market by Application
- 5.1 Global Untargeted Metabolomics Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Untargeted Metabolomics Market Size by Application (2021-2032)
- 5.3 Global Untargeted Metabolomics Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Creative Proteomics
- 6.1.1 Creative Proteomics Company Information
- 6.1.2 Creative Proteomics Business Overview
- 6.1.3 Creative Proteomics Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Creative Proteomics Untargeted Metabolomics Product Portfolio
- 6.1.5 Creative Proteomics Recent Developments
- 6.2 Metabolon
- 6.2.1 Metabolon Company Information
- 6.2.2 Metabolon Business Overview
- 6.2.3 Metabolon Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Metabolon Untargeted Metabolomics Product Portfolio
- 6.2.5 Metabolon Recent Developments
- 6.3 Alfa Chemistry
- 6.3.1 Alfa Chemistry Company Information
- 6.3.2 Alfa Chemistry Business Overview
- 6.3.3 Alfa Chemistry Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Alfa Chemistry Untargeted Metabolomics Product Portfolio
- 6.3.5 Alfa Chemistry Recent Developments
- 6.4 Novelgene Technologies
- 6.4.1 Novelgene Technologies Company Information
- 6.4.2 Novelgene Technologies Business Overview
- 6.4.3 Novelgene Technologies Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Novelgene Technologies Untargeted Metabolomics Product Portfolio
- 6.4.5 Novelgene Technologies Recent Developments
- 6.5 MtoZ-Biolabs Inc.
- 6.5.1 MtoZ-Biolabs Inc. Company Information
- 6.5.2 MtoZ-Biolabs Inc. Business Overview
- 6.5.3 MtoZ-Biolabs Inc. Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 MtoZ-Biolabs Inc. Untargeted Metabolomics Product Portfolio
- 6.5.5 MtoZ-Biolabs Inc. Recent Developments
- 6.6 CD Genomics
- 6.6.1 CD Genomics Company Information
- 6.6.2 CD Genomics Business Overview
- 6.6.3 CD Genomics Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 CD Genomics Untargeted Metabolomics Product Portfolio
- 6.6.5 CD Genomics Recent Developments
- 6.7 Metware Biotechnology Inc (Metware)
- 6.7.1 Metware Biotechnology Inc (Metware) Company Information
- 6.7.2 Metware Biotechnology Inc (Metware) Business Overview
- 6.7.3 Metware Biotechnology Inc (Metware) Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Metware Biotechnology Inc (Metware) Untargeted Metabolomics Product Portfolio
- 6.7.5 Metware Biotechnology Inc (Metware) Recent Developments
- 6.8 BGI Genomics
- 6.8.1 BGI Genomics Company Information
- 6.8.2 BGI Genomics Business Overview
- 6.8.3 BGI Genomics Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 BGI Genomics Untargeted Metabolomics Product Portfolio
- 6.8.5 BGI Genomics Recent Developments
- 6.9 APPLIED PROTEIN TECHNOLOGY
- 6.9.1 APPLIED PROTEIN TECHNOLOGY Company Information
- 6.9.2 APPLIED PROTEIN TECHNOLOGY Business Overview
- 6.9.3 APPLIED PROTEIN TECHNOLOGY Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 APPLIED PROTEIN TECHNOLOGY Untargeted Metabolomics Product Portfolio
- 6.9.5 APPLIED PROTEIN TECHNOLOGY Recent Developments
- 6.10 Suzhou PANOMIX Biomedical Tech Co.,Ltd
- 6.10.1 Suzhou PANOMIX Biomedical Tech Co.,Ltd Company Information
- 6.10.2 Suzhou PANOMIX Biomedical Tech Co.,Ltd Business Overview
- 6.10.3 Suzhou PANOMIX Biomedical Tech Co.,Ltd Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Suzhou PANOMIX Biomedical Tech Co.,Ltd Untargeted Metabolomics Product Portfolio
- 6.10.5 Suzhou PANOMIX Biomedical Tech Co.,Ltd Recent Developments
- 6.11 OBiO Technology ( Shanghai ) Corp.,Ltd.
- 6.11.1 OBiO Technology ( Shanghai ) Corp.,Ltd. Company Information
- 6.11.2 OBiO Technology ( Shanghai ) Corp.,Ltd. Business Overview
- 6.11.3 OBiO Technology ( Shanghai ) Corp.,Ltd. Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 OBiO Technology ( Shanghai ) Corp.,Ltd. Untargeted Metabolomics Product Portfolio
- 6.11.5 OBiO Technology ( Shanghai ) Corp.,Ltd. Recent Developments
- 6.12 Beijing Huayi innovation & BioTechnology Co., Ltd
- 6.12.1 Beijing Huayi innovation & BioTechnology Co., Ltd Company Information
- 6.12.2 Beijing Huayi innovation & BioTechnology Co., Ltd Business Overview
- 6.12.3 Beijing Huayi innovation & BioTechnology Co., Ltd Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Beijing Huayi innovation & BioTechnology Co., Ltd Untargeted Metabolomics Product Portfolio
- 6.12.5 Beijing Huayi innovation & BioTechnology Co., Ltd Recent Developments
- 6.13 Abace Biotechnology
- 6.13.1 Abace Biotechnology Company Information
- 6.13.2 Abace Biotechnology Business Overview
- 6.13.3 Abace Biotechnology Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Abace Biotechnology Untargeted Metabolomics Product Portfolio
- 6.13.5 Abace Biotechnology Recent Developments
- 6.14 Metabo-Profile
- 6.14.1 Metabo-Profile Company Information
- 6.14.2 Metabo-Profile Business Overview
- 6.14.3 Metabo-Profile Untargeted Metabolomics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Metabo-Profile Untargeted Metabolomics Product Portfolio
- 6.14.5 Metabo-Profile Recent Developments
7 North America
- 7.1 North America Untargeted Metabolomics Market Size (2021-2032)
- 7.2 North America Untargeted Metabolomics Market Size by Type
- 7.2.1 North America Untargeted Metabolomics Market Size by Type (2021-2026)
- 7.2.2 North America Untargeted Metabolomics Market Size by Type (2027-2032)
- 7.2.3 North America Untargeted Metabolomics Market Share by Type (2021-2032)
- 7.3 North America Untargeted Metabolomics Market Size by Application
- 7.3.1 North America Untargeted Metabolomics Market Size by Application (2021-2026)
- 7.3.2 North America Untargeted Metabolomics Market Size by Application (2027-2032)
- 7.3.3 North America Untargeted Metabolomics Market Share by Application (2021-2032)
- 7.4 North America Untargeted Metabolomics Market Size by Country
- 7.4.1 North America Untargeted Metabolomics Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Untargeted Metabolomics Market Size by Country (2021-2026)
- 7.4.3 North America Untargeted Metabolomics Market Size by Country (2027-2032)
- 7.4.4 North America Untargeted Metabolomics Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Untargeted Metabolomics Market Size (2021-2032)
- 8.2 Europe Untargeted Metabolomics Market Size by Type
- 8.2.1 Europe Untargeted Metabolomics Market Size by Type (2021-2026)
- 8.2.2 Europe Untargeted Metabolomics Market Size by Type (2027-2032)
- 8.2.3 Europe Untargeted Metabolomics Market Share by Type (2021-2032)
- 8.3 Europe Untargeted Metabolomics Market Size by Application
- 8.3.1 Europe Untargeted Metabolomics Market Size by Application (2021-2026)
- 8.3.2 Europe Untargeted Metabolomics Market Size by Application (2027-2032)
- 8.3.3 Europe Untargeted Metabolomics Market Share by Application (2021-2032)
- 8.4 Europe Untargeted Metabolomics Market Size by Country
- 8.4.1 Europe Untargeted Metabolomics Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Untargeted Metabolomics Market Size by Country (2021-2026)
- 8.4.3 Europe Untargeted Metabolomics Market Size by Country (2027-2032)
- 8.4.4 Europe Untargeted Metabolomics Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Untargeted Metabolomics Market Size (2021-2032)
- 9.2 China Untargeted Metabolomics Market Size by Type
- 9.2.1 China Untargeted Metabolomics Market Size by Type (2021-2026)
- 9.2.2 China Untargeted Metabolomics Market Size by Type (2027-2032)
- 9.2.3 China Untargeted Metabolomics Market Share by Type (2021-2032)
- 9.3 China Untargeted Metabolomics Market Size by Application
- 9.3.1 China Untargeted Metabolomics Market Size by Application (2021-2026)
- 9.3.2 China Untargeted Metabolomics Market Size by Application (2027-2032)
- 9.3.3 China Untargeted Metabolomics Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Untargeted Metabolomics Market Size (2021-2032)
- 10.2 Asia Untargeted Metabolomics Market Size by Type
- 10.2.1 Asia Untargeted Metabolomics Market Size by Type (2021-2026)
- 10.2.2 Asia Untargeted Metabolomics Market Size by Type (2027-2032)
- 10.2.3 Asia Untargeted Metabolomics Market Share by Type (2021-2032)
- 10.3 Asia Untargeted Metabolomics Market Size by Application
- 10.3.1 Asia Untargeted Metabolomics Market Size by Application (2021-2026)
- 10.3.2 Asia Untargeted Metabolomics Market Size by Application (2027-2032)
- 10.3.3 Asia Untargeted Metabolomics Market Share by Application (2021-2032)
- 10.4 Asia Untargeted Metabolomics Market Size by Country
- 10.4.1 Asia Untargeted Metabolomics Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Untargeted Metabolomics Market Size by Country (2021-2026)
- 10.4.3 Asia Untargeted Metabolomics Market Size by Country (2027-2032)
- 10.4.4 Asia Untargeted Metabolomics Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Untargeted Metabolomics Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Untargeted Metabolomics Market Size by Type
- 11.2.1 South America, Middle East & Africa Untargeted Metabolomics Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Untargeted Metabolomics Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Untargeted Metabolomics Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Untargeted Metabolomics Market Size by Application
- 11.3.1 South America, Middle East & Africa Untargeted Metabolomics Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Untargeted Metabolomics Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Untargeted Metabolomics Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Untargeted Metabolomics Market Size by Country
- 11.4.1 South America, Middle East & Africa Untargeted Metabolomics Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Untargeted Metabolomics Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Untargeted Metabolomics Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Untargeted Metabolomics Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst